
GlaxoSmithKline has terminated its three-year old agreement with Impax Pharmaceuticals to develop investigational Parkinson’s disease drug IPX066. “The decision has …
GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …

